Copyright © 2012 M. Gasparetto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. G. Sachs, D. R. Scott, and Y. Wen, “Gastric infection by Helicobacter pylori,” Current Gastroenterology Reports, vol. 13, no. 6, pp. 540–546, 2011.
2. S. Suerbaum and P. Michetti, “Helicobacter pylori infection,” The New England Journal of Medicine, vol. 347, no. 15, pp. 1175–1186, 2002. View at Publisher · View at Google Scholar · View at Scopus
3. C. Chiesa, L. Pacifico, C. Anania, E. Poggiogalle, F. Chiarelli, and J. F. Osborn, “Helicobacter pylori therapy in children: overview and challenges,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 2, pp. 405–416, 2010. View at Scopus
4. N. Muñoz, “Is Helicobacter pylori a cause of gastric cancer? An appraisal of the seroepidemiological evidence,” Cancer Epidemiology Biomarkers and Prevention, vol. 3, no. 5, pp. 445–451, 1994. View at Scopus
5. H. Suzuki, F. Franceschi, T. Nishizawa, and A. Gasbarrini, “Extragastric manifestations of Helicobacter pylori infection,” Helicobacter, vol. 16, supplement 1, pp. 65–69, 2011.
6. K. E. L. McColl, “Helicobacter pylori infection,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1597–1604, 2010. View at Publisher · View at Google Scholar · View at Scopus
7. J. B. Watson, S. F. Moss, and H. Will, “Pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen,” The American Journal of Gastroenterology, vol. 106, no. 11, pp. 1976–1977, 2011.
8. F. Parente, C. Cucino, and G. Bianchi Porro, “Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts,” Digestive and Liver Disease, vol. 35, no. 8, pp. 523–528, 2003. View at Publisher · View at Google Scholar · View at Scopus
9. K. H. Hung, B. S. Sheu, W. L. Chang, H. M. Wu, C. C. Liu, and J. J. Wu, “Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan,” Helicobacter, vol. 14, no. 1, pp. 61–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
10. P. Malfertheiner, F. Megraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report,” Gut, vol. 56, no. 6, pp. 772–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
11. N. Broutet, A. Marais, H. Lamouliatte et al., “cagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia,” Journal of Clinical Microbiology, vol. 39, no. 4, pp. 1319–1322, 2001. View at Publisher · View at Google Scholar · View at Scopus
12. G. Treiber, J. Wittig, S. Ammon, S. Walker, L. J. van Doorn, and U. Klotz, “Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a Randomized controlled trial (MACLOR study),” Archives of Internal Medicine, vol. 162, no. 2, pp. 153–160, 2002. View at Scopus
13. G. Guariso, D. Basso, C. F. Bortoluzzi et al., “GastroPanel: evaluation of the usefulness in the diagnosis of gastro-duodenal mucosal alterations in children,” Clinica Chimica Acta, vol. 402, no. 1-2, pp. 54–60, 2009. View at Publisher · View at Google Scholar · View at Scopus
14. L. M. Brown, “Helicobacter pylori: epidemiology and routes of transmission,” Epidemiologic Reviews, vol. 22, no. 2, pp. 283–297, 2000. View at Scopus
15. R. H. Hunt, S. D. Xiao, F. Megraud et al., “World gastroenterology organisation global guideline: Helicobacter pylori in developing countries,” Journal of Clinical Gastroenterology, vol. 20, no. 3, pp. 299–304, 2011. View at Scopus
16. A. O'Connor, J. P. Gisbert, D. McNamara, and C. O'Morain, “Treatment of Helicobacter pylori infection 2011,” Helicobacter, vol. 16, supplement 1, pp. 53–58, 2011. View at Scopus
17. P. Malfertheiner, F. Bazzoli, J. C. Delchier et al., “Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial,” The Lancet, vol. 377, no. 9769, pp. 905–913, 2011. View at Publisher · View at Google Scholar · View at Scopus
18. L. Fischbach and E. L. Evans, “Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori,” Alimentary Pharmacology and Therapeutics, vol. 26, no. 3, pp. 343–357, 2007. View at Publisher · View at Google Scholar · View at Scopus
19. L. Perez Aldana, M. Kato, S. Nakagawa et al., “The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance,” Helicobacter, vol. 7, no. 5, pp. 306–309, 2002. View at Publisher · View at Google Scholar · View at Scopus
20. S. Padol, Y. Yuan, M. Thabane, I. T. Padol, and R. H. Hunt, “The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis,” American Journal of Gastroenterology, vol. 101, no. 7, pp. 1467–1475, 2006. View at Publisher · View at Google Scholar · View at Scopus
21. V. De Francesco, F. Giorgio, C. Hassan et al., “Worldwide H. pylori antibiotic resistance: a systematic review,” Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 4, pp. 409–414, 2010. View at Scopus
22. S. K. Chuah, F. W. Tsay, P. I. Hsu, and D. C. Wu, “A new look at anti-Helicobacter pylori therapy,” World Journal of Gastroenterology, vol. 17, no. 35, pp. 3971–3975, 2011.
23. J. P. Gisbert, R. Pajares, and J. M. Pajares, “Evolution of Helicobacter pylori therapy from a meta-analytical perspective,” Helicobacter, vol. 12, supplement 2, pp. 50–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
24. R. M. Genta and D. Y. Graham, “Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution,” Gastrointestinal Endoscopy, vol. 40, no. 3, pp. 342–345, 1994. View at Scopus
25. F. Megraud, “Helicobacter pylori and antibiotic resistance,” Gut, vol. 56, no. 11, p. 1502, 2007. View at Publisher · View at Google Scholar · View at Scopus
26. E. Rimbara, L. A. Fischbach, and D. Y. Graham, “Optimal therapy for Helicobacter pylori infections,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 2, pp. 79–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
27. M. Selgrad and P. Malfertheiner, “Treatment of Helicobacter pylori,” Current Opinion in Gastroenterology, vol. 27, no. 6, pp. 565–570, 2011.
28. T. Kamada, K. Haruma, K. Komoto et al., “Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin,” Helicobacter, vol. 4, no. 3, pp. 204–210, 1999. View at Scopus
29. M. Abdullahi, B. Annibale, D. Capoccia et al., “The eradication of Helicobacter pylori is affected by body mass index (BMI),” Obesity Surgery, vol. 18, no. 11, pp. 1450–1454, 2008. View at Publisher · View at Google Scholar · View at Scopus
30. J. P. A. O'Connor, I. Taneike, and C. O'Morain, “Improving compliance with Helicobacter pylori eradication therapy: when and how?” Therapeutic Advances in Gastroenterology, vol. 2, no. 5, pp. 273–279, 2009. View at Publisher · View at Google Scholar · View at Scopus
31. N. Vakil, “H. pylori treatment: new wine in old bottles,” American Journal of Gastroenterology, vol. 104, no. 1, pp. 26–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
32. M. Asaka, M. Kato, S. I. Takahashi et al., “Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition,” Helicobacter, vol. 15, no. 1, pp. 1–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
33. J. P. Gisbert and X. Calvet, “Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori,” Alimentary Pharmacology and Therapeutics, vol. 2011, no. 34, pp. 604–617, 2011. View at Publisher · View at Google Scholar · View at Scopus
34. Y. Wenzhen, L. Yumin, G. Quanlin et al., “Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials,” Internal Medicine, vol. 49, no. 12, pp. 1103–1109, 2010. View at Publisher · View at Google Scholar · View at Scopus
35. L. G. Coelho, R. Leon-Barua, and E. M. Quigley, “Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE),” The American Journal of Gastroenterology, vol. 95, no. 10, pp. 2688–2691, 2000.
36. T. Furuta and D. Y. Graham, “Pharmacologic aspects of eradication therapy for Helicobacter pylori infection,” Gastroenterology Clinics of North America, vol. 39, no. 3, pp. 465–480, 2010. View at Publisher · View at Google Scholar · View at Scopus
37. K. L. Chan, H. Zhou, D. K. K. Ng, and P. K. H. Tam, “A prospective study of a one-week nonbismuth quadruple therapy for childhood Helicobacter pylori infection,” Journal of Pediatric Surgery, vol. 36, no. 7, pp. 1008–1011, 2001. View at Publisher · View at Google Scholar · View at Scopus
38. P. M. Neville, S. Everett, H. Langworthy et al., “The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 4, pp. 497–501, 1999. View at Publisher · View at Google Scholar · View at Scopus
39. T. Furuta, Y. Sagehashi, N. Shirai et al., “Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection,” Clinical Gastroenterology and Hepatology, vol. 3, no. 6, pp. 564–573, 2005. View at Publisher · View at Google Scholar · View at Scopus
40. W. D. Chey and B. C. Y. Wong, “American College of Gastroenterology guideline on the management of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
41. L. G. Coelho, R. Leon-Barua, and E. M. M. Quigley, “Latin-American consensus conference on Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 95, no. 10, pp. 2688–2691, 2000. View at Publisher · View at Google Scholar · View at Scopus
42. D. Y. Graham and L. Fischbach, “Helicobacter pylori treatment in the era of increasing antibiotic resistance,” Gut, vol. 59, no. 8, pp. 1143–1153, 2010. View at Publisher · View at Google Scholar · View at Scopus
43. L. Laine, M. B. Fennerty, M. Osato et al., “Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials,” American Journal of Gastroenterology, vol. 95, no. 12, pp. 3393–3398, 2000. View at Publisher · View at Google Scholar · View at Scopus
44. N. Vakil, F. Lanza, H. Schwartz, and J. Barth, “Seven-day therapy for Helicobacter pylori in the United States,” Alimentary Pharmacology and Therapeutics, vol. 20, no. 1, pp. 99–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
45. M. J. R. Janssen, A. H. A. M. Van Oijen, A. L. M. Verbeek, J. B. M. J. Jansen, and W. A. De Boer, “A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 5, pp. 613–624, 2001. View at Publisher · View at Google Scholar · View at Scopus
46. N. S. Jafri, C. A. Hornung, and C. W. Howden, “Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment,” Annals of Internal Medicine, vol. 148, no. 12, pp. 923–931, 2008. View at Scopus
47. L. Boyanova and I. Mitov, “Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents,” Expert Review of Anti-Infective Therapy, vol. 8, no. 1, pp. 59–70, 2010. View at Scopus
48. W. D. Chey and B. C. Y. Wong, “American College of Gastroenterology guideline on the management of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
49. S. Miura and R. Hokari, “Seeking an optimal eradication therapy for Helicobacter pylori infection,” Journal of Gastroenterology and Hepatology, vol. 27, pp. 1–9, 2012.
50. E. Gené, X. Calvet, R. Azagra, and J. P. Gisbert, “Triple vs. Quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 5, pp. 543–544, 2003. View at Publisher · View at Google Scholar · View at Scopus
51. M. Hojo, H. Miwa, A. Nagahara, and N. Sato, “Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection,” Scandinavian Journal of Gastroenterology, vol. 36, no. 7, pp. 690–700, 2001. View at Scopus
52. J. P. Gisbert and A. G. McNicholl, “Maintenance of Helicobacter pilori eradication rates with triple therapy over 12 years in a Spanish Hospital,” Helicobacter, vol. 17, no. 2, pp. 160–161, 2012.
53. M. A. Webber and L. J. V. Piddock, “The importance of efflux pumps in bacterial antibiotic resistance,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 1, pp. 9–11, 2003. View at Publisher · View at Google Scholar · View at Scopus
54. K. Murakami, T. Fujioka, T. Okimoto, R. Sato, M. Kodama, and M. Nasu, “Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy,” International Journal of Antimicrobial Agents, vol. 19, no. 1, pp. 67–70, 2002. View at Publisher · View at Google Scholar · View at Scopus
55. D. Vaira, A. Zullo, N. Vakil et al., “Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial,” Annals of Internal Medicine, vol. 146, no. 8, pp. 556–563, 2007. View at Scopus
56. L. Gatta, N. Vakil, G. Leandro, F. Di Mario, and D. Vaira, “Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children,” American Journal of Gastroenterology, vol. 104, no. 12, pp. 3069–3079, 2009. View at Publisher · View at Google Scholar · View at Scopus
57. R. Francavilla, E. Lionetti, and L. Cavallo, “Sequential treatment for Helicobacter pylori eradication in children,” Gut, vol. 57, no. 8, p. 1178, 2008. View at Scopus
58. J. L. Tong, Z. H. Ran, J. Shen, and S. D. Xiao, “Sequential therapy vs. Standard triple therapies for Helicobacter pylori infection: a meta-analysis,” Journal of Clinical Pharmacy and Therapeutics, vol. 34, no. 1, pp. 41–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
59. R. J. F. Laheij, L. G. M. Van Rossum, J. B. M. J. Jansen, H. Straatman, and A. L. M. Verbeek, “Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta-analysis,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 7, pp. 857–864, 1999. View at Publisher · View at Google Scholar · View at Scopus
60. E. R. Greenberg, G. L. Anderson, D. R. Morgan et al., “14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial,” The Lancet, vol. 378, no. 9790, pp. 507–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
61. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, “Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?” Helicobacter, vol. 16, no. 2, pp. 146–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
62. S. Miehlke, C. Kirsch, W. Schneider-Brachert et al., “A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin,” Helicobacter, vol. 8, no. 4, pp. 310–319, 2003. View at Publisher · View at Google Scholar · View at Scopus
63. T. A. Attumi and D. Y. Graham, “Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study,” Journal of Gastroenterology and Hepatology, vol. 27, pp. 59–61, 2012.
64. R. J. Saad, P. Schoenfeld, M. K. Hyungjin, and W. D. Chey, “Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis,” American Journal of Gastroenterology, vol. 101, no. 3, pp. 488–496, 2006. View at Publisher · View at Google Scholar · View at Scopus
65. P. Basu, K. Rayapudi, T. Pacana, et al., “A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori,” The American Journal of Gastroenterology, vol. 106, no. 11, pp. 1970–1975, 2011.
66. S. Baba, Y. Oishi, Y. Watanabe, et al., “Gastric wash-based molecular testing for antibiotic resistance in Helicobacter pylori,” Digestion, vol. 84, no. 4, pp. 299–305, 2011.
67. H. Szajewska, A. Horvath, and A. Piwowarczyk, “Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment,” Alimentary Pharmacology and Therapeutics, vol. 32, no. 9, pp. 1069–1079, 2010. View at Publisher · View at Google Scholar · View at Scopus
68. R. Francavilla, E. Lionetti, S. P. Castellaneta et al., “Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study,” Helicobacter, vol. 13, no. 2, pp. 127–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
69. S. Koletzko, N. L. Jones, K. J. Goodman et al., “Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children,” Journal of Pediatric Gastroenterology and Nutrition, vol. 53, no. 2, pp. 230–243, 2011. View at Publisher · View at Google Scholar · View at Scopus
70. A. Alakkari, A. Zullo, and H. J. O’Connor, “Helicobacter pylori and nonmalignant diseases,” Helicobacter, vol. 16, supplement 1, pp. 33–37.
71. A. C. De Vries and E. J. Kuipers, “Helicobacter pylori infection and Nonmalignant Diseases,” Helicobacter, vol. 15, supplement 1, pp. 29–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
72. M. Rathbone and B. Rathbone, “Helicobacter pylori and gastric cancer,” Recent Results in Cancer Research, vol. 185, pp. 83–97, 2011.
73. D. Cullen, G. Hawkey, D. Greenwood, et al., “Helicobacter pylori and gastroesophageal reflux disease: a Community-Based Study,” Helicobacter, vol. 13, no. 5, pp. 352–360, 2008.
74. D. Y. Graham, “The changing epidemiology of GERD: geography and Helicobacter pylori,” American Journal of Gastroenterology, vol. 98, no. 7, pp. 1462–1470, 2003. View at Scopus
75. A. S. Raghunath, A. P. S. Hungin, D. Wooff, and S. Childs, “Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis,” Alimentary Pharmacology and Therapeutics, vol. 20, no. 7, pp. 733–744, 2004. View at Publisher · View at Google Scholar · View at Scopus
76. B. Qian, S. Ma, L. Shang, J. Qian, and G. Zhang, “Effects of Helicobacter pylori eradication on gastroesophageal reflux disease,” Helicobacter, vol. 16, no. 4, pp. 255–265, 2011. View at Publisher · View at Google Scholar · View at Scopus
77. M. Rathbone and B. Rathbone, “Helicobacter pylori and gastric cancer,” Recent Results in Cancer Research, vol. 185, pp. 83–97, 2011.
78. M. Selgrad, J. Bornschein, T. Rokkas, and P. Malfertheiner, “Clinical aspects of gastric cancer and Helicobacter pylori-screening, prevention, and treatment,” Helicobacter, vol. 15, supplement 1, pp. 40–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
79. T. Yoshida, H. Ono, A. Kuchiba, N. Saeki, and H. Sakamoto, “Genome-wide germline analyses on cancer susceptibility and GeMDBJ database: gastric cancer as an example,” Cancer Science, vol. 101, no. 7, pp. 1582–1589, 2010. View at Publisher · View at Google Scholar · View at Scopus